“Blue Owl Capital’s Buy Rating Sustains Despite Market Downturn: TD Cowen”
Despite a recent decline in stock, TD Cowen maintains its confidence in Blue Owl Capital (NYSE:OWL), underpinning its belief in the firm's strong fundamentals and resilient business model. With a $30 price target, undervalued stocks and a robust dividend yield, Blue Owl presents as an attractive investment amidst current macroeconomic uncertainties. Read more
Read More
“William Blair Positive on Ocular Therapeutix Coverage”
William Blair fuels optimism with new coverage on biopharmaceutical company, Ocular Therapeutix. The firm's guidance reflects a positive stance owing to potential success of Ocular's Axpaxli, an innovative nAMD treatment. With ongoing Phase III trials and plans of expansion beyond nAMD treatment, Ocular Therapeutix presents a promising investment opportunity. Read more
Read More
“Elliott’s Board Nomination Rejected by Phillips 66 Shareholders”
Phillips 66 urges shareholders to reject board nominations by activist investor, Elliott Investment Management, citing a focus on short-term gains at the cost of long-term stability. The energy giant emphasises its commitment to sustainable growth, robust governance, and rejects Elliott's proposals as disruptive and grounded in unrealistic expectations. Read more
Read More